<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01261143</url>
  </required_header>
  <id_info>
    <org_study_id>BK-C-0701-301</org_study_id>
    <nct_id>NCT01261143</nct_id>
  </id_info>
  <brief_title>Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy</brief_title>
  <official_title>Phase III Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bukwang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bukwang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the:&#xD;
&#xD;
      Primary end point&#xD;
&#xD;
        -  change of Total symptom score&#xD;
&#xD;
      Secondary end point&#xD;
&#xD;
        -  neurological test&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      total symptom score shall be calculated from the data of burning, numbness, stabbing pain,&#xD;
      paraesthesiae.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSS</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>BK-C-0701, diabetic neuropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>alpha lipoic acid, diabetic neuropathy, capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BK-C-0701</intervention_name>
    <description>tablet, 8 weeks</description>
    <arm_group_label>BK-C-0701, diabetic neuropathy</arm_group_label>
    <arm_group_label>alpha lipoic acid, diabetic neuropathy, capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus (Type I or II), as defined by the American Diabetes Association,&#xD;
             1997, lasting 1 year and is well-controlled.&#xD;
&#xD;
          -  Patient with symmetric sensory-motor Diabetic Neuropathy which is above stage 2&#xD;
&#xD;
          -  Result of pin-prick test is 'absent' or 'reduced'&#xD;
&#xD;
          -  HbA1C &lt;10%&#xD;
&#xD;
          -  Total Symptom Score ≥ 4 points&#xD;
&#xD;
          -  At least 1 of the 4 symptoms of the TSS must have occurred continuously over the last&#xD;
             3 months.&#xD;
&#xD;
          -  Patient over 19 years of age&#xD;
&#xD;
          -  Female who is postmenopausal or is willing to use an effective method of contraception&#xD;
             during the study (Effective method=IUD, spermicide with condom, abstinence) or is&#xD;
             surgically sterile (underwent a total hysterectomy or bilateral tubal ligation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who has Proximal asymmetric neuropathy, cranial neuropathies, truncal&#xD;
             radiculopathy, diabetic plexopathies, acute or active mononeuropathies (cranial&#xD;
             neuropathies, post-herpes neuralgias)&#xD;
&#xD;
          -  Patient who has Neuropathy from alcohol, drug (cisplatin, taxol , etcs), malignant&#xD;
             cancer or has a medical history of nerve system disease such as Parkinson's disease/&#xD;
             epilepsy/ Multiple sclerosis, etcs.&#xD;
&#xD;
          -  Patient who has nerve system disease which can cause sensory loss Myopathy of any&#xD;
             cause.&#xD;
&#xD;
          -  Peripheral vascular disease severe enough to cause ischemic ulcers or limb ischemia.&#xD;
&#xD;
          -  Patients with diabetic proliferating retinopathy requiring immediately therapy and&#xD;
             impending blindness.&#xD;
&#xD;
          -  Patients with any active neoplastic disease except benign tumor or nonrecurrent&#xD;
             malignant tumor for 5 years.&#xD;
&#xD;
          -  Patients with clinically significant cardiac, pulmonary, gastrointestinal,&#xD;
             haematological, or endocrine disease that may confound interpretation of the study&#xD;
             results or prevent the patient from completing the study.&#xD;
&#xD;
          -  Patients with atrial fibrillation.&#xD;
&#xD;
          -  Patients who have had organ transplants of any kind.&#xD;
&#xD;
          -  Patients with significant hepatic or renal disease (AST, ALT or GGT &gt;2 times normal,&#xD;
             serum creatinine &gt;1.8 mg/dL (&gt;159 mmol/l) for males or &gt;1.6 mg/dL (&gt;141 mmol/l) for&#xD;
             females).&#xD;
&#xD;
          -  Patients with a recent history (within last 12 months) of drug or alcohol abuse.&#xD;
&#xD;
          -  Use of any investigational drug (participation in a clinical trial) within last 1&#xD;
             month.&#xD;
&#xD;
          -  History of severe or anaphylactic reaction to drugs, sulfur or biologic products.&#xD;
&#xD;
          -  Recent (within last 3 months) ketoacidosis or hypoglycaemia, necessitating hospital&#xD;
             admission.&#xD;
&#xD;
          -  Existing foot ulcers.&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  History of allergic reaction to the study medication or its excipients.&#xD;
&#xD;
          -  Psychiatric, psychological, or behavioural symptoms that would interfere with the&#xD;
             patient's ability to participate in the trial.&#xD;
&#xD;
          -  Patient who is not suitable to trial by investigator judgment.&#xD;
&#xD;
          -  Patient who does not write informed consent prior to start of trial and cannot comply&#xD;
             with the trial requirements.&#xD;
&#xD;
          -  Antioxidant therapy (vitamins E &gt; 400 IU, C &gt; 200 mg, and beta-Carotene &gt; 30 mg) or&#xD;
             pentoxyphylline within last 1 month before start of trial.&#xD;
&#xD;
          -  Use of thioctic acid (&gt; 50 mg), evening primrose oil or any other gamma-linolenic acid&#xD;
             containing substance within the last 3 months.&#xD;
&#xD;
          -  Use of analgesic within &gt;5times of a half-life before administration of&#xD;
             investigational medication.&#xD;
&#xD;
          -  Use of anticonvulsants(include Pregabalin), antidepressants within 4 weeks before&#xD;
             administration of investigational medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyung soo Ko</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2010</study_first_posted>
  <last_update_submitted>April 24, 2012</last_update_submitted>
  <last_update_submitted_qc>April 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <name_title>Hunjun Jang</name_title>
    <organization>bukwang</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

